<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04273373</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-AKI-03</org_study_id>
    <nct_id>NCT04273373</nct_id>
  </id_info>
  <brief_title>Low Dose Albumin Versus Standard Dose Albumin in Spontaneous Bacterial Peritonitis With Acute Kidney Injury.</brief_title>
  <official_title>A Randomized Non-inferiority Trial Comparing Low Dose Albumin Versus Standard Dose Albumin in Spontaneous Bacterial Peritonitis With Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AIM:- A randomized non-inferiority trial comparing low dose albumin versus standard dose&#xD;
      albumin in Spontaneous Bacterial Peritonitis with acute kidney injury&#xD;
&#xD;
      Methodology In this non-inferior randomized controlled trial one group will receive Low dose&#xD;
      albumin: 20% albumin.5 g/kg at diagnosis and 0.5 g/kg till 5 days and other group will&#xD;
      receive Standard dose albumin: 20% albumin1.5 g/kg at diagnosis and 1 g/kg at 48 h (duration&#xD;
      of infusion 24 hours).&#xD;
&#xD;
      Study population: Patients of age &gt; 18 years of age with cirrhosis of liver who are admitted&#xD;
      in ward/Intensive Care Unit diagnosed with Spontaneous Bacterial Peritonitis.&#xD;
&#xD;
      Study design: Randomized controlled trial Study period: September 2019- September 2020 Sample&#xD;
      size: 300 (150 cases in each group) If there is a true difference in favour of the&#xD;
      experimental treatment of 5 % then 270 patients are required to be 80% sure that the upper&#xD;
      limit of a one sided 95% confidence interval (or equivalently a 90 % two-sided confidence&#xD;
      interval) will exclude a difference in favour of the standard group of more than 5 %. And if&#xD;
      the investigators consider 10% drop out final sample size is 270+30=300. 150 in each limb.&#xD;
      Cases will be randomly allocated in 2 groups by block randomization method with block size&#xD;
      taken as 10.&#xD;
&#xD;
      Monitoring and assessment: all the parameters of the objective and also noted any adverse&#xD;
      effects.&#xD;
&#xD;
      Adverse Effects: Nausea, Vomiting, Fever with chills, dyspnea Stopping Rule: in the event of&#xD;
      any of the adverse effects during therapy.&#xD;
&#xD;
      Expected Outcome of the project:&#xD;
&#xD;
      Proportion of patients having progression of Acute Kidney Injury by day 7&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Anticipated">February 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients having progression of Acute Kidney Injury in both groups</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with resolution of Spontaneous Bacterial Peritonitis in both groups</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PRA (Plasma Renin Activity) in both groups</measure>
    <time_frame>Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in TNF-alpha (Tumor Necrosis Factor) in both groups</measure>
    <time_frame>Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in IL-6 (Interleukin) in both groups</measure>
    <time_frame>Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who will develop volume overload in both groups</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who will not survive in both groups.</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who will not survive in both groups.</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Spontaneous Bacterial Peritonitis</condition>
  <arm_group>
    <arm_group_label>Standard dose albumin+SOC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20% albumin1.5 g/kg at diagnosis and 1 g. SOC (Standard of Care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose albumin+SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20% albumin.5 g/kg at diagnosis and 0.5 g/kg. SOC (Standard of Care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low Dose Albumin</intervention_name>
    <description>20% albumin.5 g/kg at diagnosis and 0.5 g/kg till 5days</description>
    <arm_group_label>Low dose albumin+SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard dose Albumin</intervention_name>
    <description>20% albumin1.5 g/kg at diagnosis and 1 g/kg at 48 h (duration of infusion 24 hours).</description>
    <arm_group_label>Standard dose albumin+SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. &gt;18 years of age&#xD;
&#xD;
          2. Cirrhosis with SBP (community acquired, health care associated and nosocomial) and&#xD;
             baseline serum bilirubin ≥4 mg/dl or SCr ≥ 1 mg/dl.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Antibiotic treatment within one week before the diagnosis of SBP (except for&#xD;
             prophylactic treatment with norfloxacin)&#xD;
&#xD;
          2. Significant cardiac failure, pulmonary disease&#xD;
&#xD;
          3. Known CKD ( Chronic Kidney Disease)or findings suggestive of organic nephropathy&#xD;
             (proteinuria, haematuria, or Abnormal findings on renal USG)&#xD;
&#xD;
          4. Hepatocellular carcinoma&#xD;
&#xD;
          5. HIV (Human Immunodeficiency Virus) infection;&#xD;
&#xD;
          6. GI (Gastrointestinal) bleed within 1 month before the study&#xD;
&#xD;
          7. Ileus&#xD;
&#xD;
          8. Grade 3 to 4 hepatic encephalopathy&#xD;
&#xD;
          9. Other types of infection&#xD;
&#xD;
         10. Shock&#xD;
&#xD;
         11. Presence of any potential causes of dehydration (such as diarrhoea or an intense&#xD;
             response to diuretic treatment) within one week before the diagnosis of SBP).&#xD;
&#xD;
         12. Baseline serum bilirubin &lt;4 mg/dl or S. Cr &lt; 1 mg/dl&#xD;
&#xD;
         13. Serum creatinine level of &gt; 3.0 mg/dl.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Pinakee Sunder Kar, MD</last_name>
    <phone>01146300000</phone>
    <email>pinakeesunder@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Pinakee Sunder Kar, MD</last_name>
      <phone>01146300000</phone>
      <email>pinakeesunder@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

